Story perspectives

Novo Nordisk's Wegovy Launch Sparks Weight-Loss Drug Race

1/17/2026

31 5

Summary

Story summary

Novo Nordisk launched its oral weight-loss pill Wegovy on January 5, 2026, with 3,071 prescriptions in four days.
The FDA approved the drug in December 2025, offering a convenient alternative to the injectable and potentially improving adherence.
Insurance coverage remains inconsistent, with many plans excluding obesity treatments.
Eli Lilly and Company plans to launch its own oral weight-loss drug, orforglipron, later this year, intensifying glucagon-like peptide-1 (GLP-1) competition.

History

Historical Context

The FDA approved fenfluramine in 1973 as an appetite suppressant, leading to its combination with phentermine, known as Fen-Phen, in the 1980s. However, by 1997, concerns over severe cardiovascular side effects prompted its withdrawal, affecting millions. The recent introduction of Novo Nordisk's Wegovy and Eli Lilly's orforglipron highlights ongoing efforts to address obesity, emphasizing the need for careful regulatory oversight in pharmaceutical innovations.

1 of 2

Story summary

Novo Nordisk launched its oral weight-loss pill Wegovy on January 5, 2026, with 3,071 prescriptions in four days.
The FDA approved the drug in December 2025, offering a convenient alternative to the injectable and potentially improving adherence.
Insurance coverage remains inconsistent, with many plans excluding obesity treatments.
Eli Lilly and Company plans to launch its own oral weight-loss drug, orforglipron, later this year, intensifying glucagon-like peptide-1 (GLP-1) competition.

1 / 2